Key result
Recent trials and evolving technology, such as cardiac resynchronization capabilities, are expanding the indications for implantable cardioverter-defibrillators in high-risk patients.
Answers are grounded in this paper and cite their sources.
This review summarizes trials expanding the indications for ICDs, particularly for primary prevention of sudden death in high-risk patients.
PURPOSE OF REVIEW: This article reviews multiple secondary and primary prevention trials that have expanded the indications for implantable cardioverter-defibrillators (ICDs). RECENT FINDINGS: Most studies performed over the last several years have concentrated on the role of ICDs in high-risk patients for the primary prevention of sudden death. Several recent trials that have been completed but not published are also reviewed. SUMMARY: Data from recently completed trials and evolving ICD technology, such as ICDs with cardiac resynchronization capabilities, will alter indications for ICDs in the near future.
No takes yet. Share an insight, caveat, or question.
Gerald V. Naccarelli (2004) conducted a review in High-risk patients for primary prevention of sudden death. Implantable cardioverter-defibrillators (ICDs) was evaluated. Recent trials and evolving technology, such as cardiac resynchronization capabilities, are expanding the indications for implantable cardioverter-defibrillators in high-risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: